ES2705400T3 - Sulfonas heterocíclicas como moduladores de ROR gamma - Google Patents

Sulfonas heterocíclicas como moduladores de ROR gamma Download PDF

Info

Publication number
ES2705400T3
ES2705400T3 ES15700818T ES15700818T ES2705400T3 ES 2705400 T3 ES2705400 T3 ES 2705400T3 ES 15700818 T ES15700818 T ES 15700818T ES 15700818 T ES15700818 T ES 15700818T ES 2705400 T3 ES2705400 T3 ES 2705400T3
Authority
ES
Spain
Prior art keywords
substituted
alkyl
hydrogen
independently
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15700818T
Other languages
English (en)
Spanish (es)
Inventor
Jingwu Duan
T G Murali Dhar
Bin Jiang
Ananta Karmakar
Arun Kumar Gupta
Zhonghui Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2705400T3 publication Critical patent/ES2705400T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96Sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES15700818T 2014-01-06 2015-01-05 Sulfonas heterocíclicas como moduladores de ROR gamma Active ES2705400T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461923904P 2014-01-06 2014-01-06
PCT/US2015/010090 WO2015103510A1 (en) 2014-01-06 2015-01-05 Heterocyclic sulfone as ror-gamma modulators

Publications (1)

Publication Number Publication Date
ES2705400T3 true ES2705400T3 (es) 2019-03-25

Family

ID=52392247

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15700818T Active ES2705400T3 (es) 2014-01-06 2015-01-05 Sulfonas heterocíclicas como moduladores de ROR gamma

Country Status (6)

Country Link
US (1) US9637455B2 (enExample)
EP (1) EP3092221B1 (enExample)
JP (1) JP6476205B2 (enExample)
CN (1) CN106061956B (enExample)
ES (1) ES2705400T3 (enExample)
WO (1) WO2015103510A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3044219A1 (en) 2013-09-09 2016-07-20 Bristol-Myers Squibb Company Rorgamma modulators
EP3046906B1 (en) 2013-09-20 2017-08-16 Bristol-Myers Squibb Company Ror gamma modulators
EP3092216B1 (en) 2014-01-06 2018-12-12 Bristol-Myers Squibb Company Carbocyclic sulfone ror gamma modulators
CN106061956B (zh) 2014-01-06 2021-03-12 百时美施贵宝公司 作为RORγ调节剂的杂环砜
US9708253B2 (en) 2014-01-06 2017-07-18 Bristol-Myers Squibb Company Cyclohexyl sulfone RORγ modulators
CA2936116A1 (en) 2014-01-06 2015-07-09 Bristol-Myers Squibb Company Pyrrolidinyl sulfone derivatives and their use as ror gamma modulators
SMT201900706T1 (it) 2014-10-30 2020-01-14 Janssen Pharmaceutica Nv Tiazoli sostituiti con ammide come modulatori di rorgammat
JOP20200117A1 (ar) 2014-10-30 2017-06-16 Janssen Pharmaceutica Nv كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t
RS58250B1 (sr) 2014-10-30 2019-03-29 Janssen Pharmaceutica Nv Tiazoli kao modulatori roryt
ES2887087T3 (es) 2015-05-07 2021-12-21 Bristol Myers Squibb Co Sulfonas tricíclicas como moduladores ROR gamma
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為RORγT調節劑之6-胺基吡啶-3-基噻唑
KR102599437B1 (ko) * 2016-11-09 2023-11-07 브리스톨-마이어스 스큅 컴퍼니 Ror 감마 조정제로서의 트리시클릭 술폰
ES2928246T3 (es) 2018-06-18 2022-11-16 Janssen Pharmaceutica Nv 6-aminopiridin-3-il pirazoles como moduladores de RORyt
US10975037B2 (en) 2018-06-18 2021-04-13 Janssen Pharmaceutica Nv Phenyl substituted pyrazoles as modulators of RORγt
JP2021527660A (ja) 2018-06-18 2021-10-14 ヤンセン ファーマシューティカ エヌ.ベー. RORγtのモジュレータとしてのフェニル及びピリジニル置換イミダゾール
CN112292373A (zh) 2018-06-18 2021-01-29 詹森药业有限公司 作为RORγt的调节剂的吡啶基吡唑类

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE735866C (de) * 1941-01-17 1943-06-11 Ig Farbenindustrie Ag Verfahren zur Darstellung von Aminoalkylsulfonverbindungen
US2802013A (en) * 1954-02-12 1957-08-06 Searle & Co 2-(oxo and imino)-3-(phenyl and halophenyl)-tetrahydrofuransulfones and processes for the manufacture thereof
US3016403A (en) * 1955-07-29 1962-01-09 Searle & Co 1-aryl-3-hydroxypropyl sulfones and processes
US2812330A (en) 1956-05-02 1957-11-05 Searle & Co Sulfone derivatives of 2, 6-piperidinedione
GB0108591D0 (en) * 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
AU2002367147A1 (en) 2001-12-27 2003-07-15 Daiichi Pharmaceutical Co., Ltd. Beta-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS
US20110251172A1 (en) * 2008-08-13 2011-10-13 Rivkin Alexey A Purine derivatives for treatment of alzheimer's disease
US20130190356A1 (en) * 2011-12-22 2013-07-25 Genentech, Inc. Benzyl sulfonamide derivatives as rorc modulators
US9266827B2 (en) 2012-05-08 2016-02-23 Merck Sharp & Dohme Corp. Bicyclic sulfone compounds for inhibition of RORgamma activity and the treatment of disease
WO2014028669A1 (en) * 2012-08-15 2014-02-20 Biogen Idec Ma Inc. Novel compounds for modulation of ror-gamma activity
WO2014062938A1 (en) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Rory modulators
EP3044219A1 (en) 2013-09-09 2016-07-20 Bristol-Myers Squibb Company Rorgamma modulators
EP3046906B1 (en) 2013-09-20 2017-08-16 Bristol-Myers Squibb Company Ror gamma modulators
US9708253B2 (en) 2014-01-06 2017-07-18 Bristol-Myers Squibb Company Cyclohexyl sulfone RORγ modulators
CN106061956B (zh) 2014-01-06 2021-03-12 百时美施贵宝公司 作为RORγ调节剂的杂环砜
CA2936116A1 (en) 2014-01-06 2015-07-09 Bristol-Myers Squibb Company Pyrrolidinyl sulfone derivatives and their use as ror gamma modulators
EP3092216B1 (en) 2014-01-06 2018-12-12 Bristol-Myers Squibb Company Carbocyclic sulfone ror gamma modulators

Also Published As

Publication number Publication date
CN106061956B (zh) 2021-03-12
US20160326115A1 (en) 2016-11-10
WO2015103510A1 (en) 2015-07-09
JP6476205B2 (ja) 2019-02-27
US9637455B2 (en) 2017-05-02
JP2017501237A (ja) 2017-01-12
EP3092221B1 (en) 2018-10-17
EP3092221A1 (en) 2016-11-16
CN106061956A (zh) 2016-10-26

Similar Documents

Publication Publication Date Title
ES2705400T3 (es) Sulfonas heterocíclicas como moduladores de ROR gamma
ES2713681T3 (es) Moduladores de ROR gamma de sulfona carbocíclica
ES2704460T3 (es) Moduladores de ROR gamma de ciclohexilsulfona
US9458171B2 (en) Pyrrolidinyl sulfone RORγ modulators
US10711020B2 (en) Tricyclic sulfones as RORγ modulators
ES2872005T3 (es) Sulfonas heterocíclicas como moduladores de ROR gamma
WO2018071314A1 (en) Tricyclic sulfones as ror gamma modulators
US20230348437A1 (en) Compounds, compositions and methods
US11078186B2 (en) ROR γ modulators
ES2820535T3 (es) Sulfonas tricíclicas como moduladores de ROR gamma